hVIVO plc (LON: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed a contract with Inhalon Biopharma, Inc. (Inhalon), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections, to assess its inhaled IN-002 antiviral candidate (IN-002) using the hVIVO Respiratory Syncytial Virus (RSV) Human Challenge Model.
Highlights
· hVIVO RSV human challenge trial to test IN-002, an inhaled (mucosal) antiviral candidate to treat RSV infection
· FluCamp to recruit healthy volunteers to test IN-002 efficacy across three dosing levels
· Trial expected to commence in H2 2026 with the majority of revenue recognised in 2026
The Phase 2a randomised, double-blinded placebo-controlled human challenge trial will evaluate the safety, pharmacokinetics and antiviral activity of inhaled IN-002 following RSV infection, at three dose levels. hVIVO will leverage its in-house volunteer recruitment arm, FluCamp, to enrol healthy volunteers into the study. The study is expected to commence in H2 2026 at hVIVO’s state-of-the-art quarantine facilities in Canary W
